The research progress of Aurora-B kinase and its inhibitors.
- Author:
Dan-Dan DONG
1
;
Yan-Yan XIAO
;
Wei LIU
;
Hong-Gang ZHOU
;
Cheng YANG
Author Information
1. College of Sciences, Tianjin University of Science and Technology, Tianjin 300457, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Aurora Kinase B;
antagonists & inhibitors;
genetics;
metabolism;
Enzyme Activation;
Humans;
Mitosis;
Neoplasms;
drug therapy;
Protein Kinase Inhibitors;
pharmacology;
therapeutic use;
RNA, Messenger;
metabolism
- From:
Acta Pharmaceutica Sinica
2013;48(4):457-465
- CountryChina
- Language:Chinese
-
Abstract:
Aurora-B as an important kinase to adjust the cell normal mitosis is a potent target for cancer treatment. Aurora-B is overexpressed in a broad range of tumor and tumor cells are more sensitive while Aurora-B is inhibited. Due to the key role of the Aurora-B in cell mitosis, the development of its inhibitors is becoming more and more important. Several small molecules inhibit with a similar efficacy both Aurora-A and Aurora-B, however, in most cases the effects resemble Aurora-B disruption by genetic methods, indicating that Aurora-B represents an effective therapeutic target. There were several Aurora-B kinase inhibitors which had entered the clinics and displayed good antitumor activity. In this review, we will outline the functions of Aurora kinase B in normal cell division and in malignancy. We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora-B inhibitors in cancer treatment.
